Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Autor: Levis, Mark, Ravandi, Farhad, Wang, Eunice S., Baer, Maria R., Perl, Alexander, Coutre, Steven, Erba, Harry, Stuart, Robert K., Baccarani, Michele, Cripe, Larry D., Tallman, Martin S., Meloni, Giovanna, Godley, Lucy A., Langston, Amelia A., Amadori, Sergio, Lewis, Ian D., Nagler, Arnon, Stone, Richard, Yee, Karen, Advani, Anjali, Douer, Dan, Wiktor-Jedrzejczak, W., Juliusson, Gunnar, Litzow, Mark R., Petersdorf, Stephen, Sanz, Miguel, Kantarjian, Hagop M., Sato, Takashi, Tremmel, Lothar, Bensen-Kennedy, Debra M., Small, Donald, Smith, B. Douglas

Publikováno v: In Blood 24 March 2011 117(12):3294-3301

Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy

Autor: Awedan, A, Król, M, Blajer, B, Rokicka, M, Torosian, T, Urbanowska, E, Wiktor-Jedrzejczak, W

Publikováno v: In Transplantation Proceedings 2003 35(6):2349-2351

Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Autor: Auner, H, Iacobelli, S, Sbianchi, G, Knol-Bout, C, Blaise, D, Russell, N, Apperley, J, Pohlreich, D, Browne, P, Kobbe, G, Isaksson, C, Lenhoff, S, Scheid, C, Touzeau, C, Jantunen, E, Anagnostopoulos, A, Yakoub-Agha, I, Tanase, A, Schaap, N, Wiktor-Jedrzejczak, W, Krejci, M, Schönland, S, Morris, C, Garderet, L, Kröger, N

Publikováno v: Haematologica

Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d3fc843a23be3c7470c6eeca12d2344e
http://hdl.handle.net/10044/1/55412

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium.

Autor: Wiktor-Jedrzejczak, W¹, Dearden, C², de Wreede, L³, van Biezen, A³, Brinch, L⁴, Leblond, V⁵, Brune, M⁶, Volin, L⁷, Kazmi, M⁸, Nagler, A⁹, Schetelig, J¹⁰, de Witte, T¹¹, Dreger, P¹²

Publikováno v: Leukemia (08876924). May2012, Vol. 26 Issue 5, p972-976. 5p.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party

Autor: Koenecke, C., Heim, D., Biezen, A. van, Heuser, M., Aljurf, M., Kyrcz-Krzemien, S., Volin, L., Souza, C.A. de, Gedde-Dahl, T., Sengeloev, H., Schanz, U., Komarnicki, M., Arroyo, C.H., Tholouli, E., Gluckman, E., Esquirol, A., Yakoub-Agha, I., Gurman, G., Olavarria, E., Kroger, N., Rovira, M., Kahls, P., Alegre, A., Nemet, D., Stamatovic, D., Vitek, A., Hamladji, R., Hellmann, A., Chybicka, A., Wiktor-Jedrzejczak, W., Maiolino, A., Borne, P.V.D., Chevallier, P., Littlewood, T., Crawley, C., Mistrik, M., Schafer-Eckart, K., Orchard, K., Maertens, J., Lint, M. van, Ethell, M., Vettenranta, K., Broom, A., Deconinck, E., Schaap, N., Petersen, E., Espiga, C.R., Bartolomeo, P. di, Brown, P., Beelen, D., Leblond, V., Leleu, X., Carlson, K., Milpied, N., Collin, M., Johansson, J., Cairoli, R., Serwe, H., Schleuning, M., Ozturk, M., Lisukov, I.A., Robinson, S., Uckan-Cetinkaya, D., Rohrlich, P., Visani, G., Merli, F., Sanz, M., Michallet, M., Halaburda, K., O'Brien, T., Jindra, P., Feldman, L., Theobald, M., Favre, C., Rodeghiero, F., Finke, J.

Publikováno v: Bone Marrow Transplantation, 51(9), 1259-1261
BONE MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b8c07af75f46016a80c1390fcc29af
https://pubmed.ncbi.nlm.nih.gov/27111041